Biological Material Transfer Agreement Template for Canada

A Biological Material Transfer Agreement (MTA) is a specialized legal contract that governs the transfer of biological materials between research institutions, universities, biotechnology companies, and other organizations in Canada. You need this document whenever you're transferring or receiving valuable biological resources such as cell lines, plasmids, DNA sequences, antibodies, tissue samples, or other biological specimens for research, evaluation, or commercial purposes.

When do you need this document?

You require an MTA when your research institution is providing biological materials to another organization for scientific research or when you're receiving materials from external sources. This includes transfers between universities and pharmaceutical companies for drug development, sharing of cell lines between academic institutions for collaborative research, or transferring genetically modified organisms to biotechnology companies for commercial evaluation. The agreement is also necessary when healthcare institutions provide biological samples to research laboratories or when government research facilities share materials with private sector partners. Any transfer involving human pathogens, toxins, or materials that could pose biosafety risks particularly requires this documentation under Canadian law.

Key legal considerations

Your MTA must clearly define the scope of permitted use, whether for research-only purposes or including commercial applications. You need to address intellectual property rights, specifying whether the provider retains ownership of any discoveries or innovations derived from the materials. Publication and data sharing restrictions should be explicitly outlined, including requirements for acknowledgment and potential review periods before publication. The agreement must establish liability allocation, insurance requirements, and indemnification clauses to protect both parties. You should include termination provisions specifying return or destruction of materials upon agreement expiry. Commercialization terms are crucial, covering licensing rights, royalty payments, and revenue sharing if the materials lead to marketable products or services.

Legal requirements in Canada

Under Canadian law, your MTA must comply with the Human Pathogens and Toxins Act (HPTA) when transferring controlled materials, ensuring proper licensing and safety protocols are followed. You must adhere to Canadian Biosafety Standards (CBS) for containment levels, operational practices, and verification testing requirements. The agreement should address Export and Import Permits Act requirements if materials cross international borders or involve controlled substances. Privacy considerations under PIPEDA apply when biological materials involve human specimens with associated personal information. Patent Act compliance is necessary to protect potential intellectual property rights arising from the transferred materials. Provincial regulations may impose additional requirements depending on your jurisdiction and the nature of the biological materials being transferred.